These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24297862)

  • 1. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
    Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
    Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
    Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
    Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Gopalakrishnapillai A; Kolb EA; McCahan SM; Barwe SP
    Leuk Res; 2017 Jul; 58():91-97. PubMed ID: 28505595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
    Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
    Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
    J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
    Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications.
    El-Samahy MH; Adly AA; Ismail EA; Salah NY
    J Diabetes Complications; 2015; 29(1):120-6. PubMed ID: 25113439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
    Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Front Immunol; 2017; 8():1482. PubMed ID: 29163543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
    Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
    J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia.
    Wan Y; Zhang C; Xu Y; Wang M; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang Y; Wang J
    BMC Cancer; 2020 May; 20(1):472. PubMed ID: 32456622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
    Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
    Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
    Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
    Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
    Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
    Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
    Craddock CF; Houlton AE; Quek LS; Ferguson P; Gbandi E; Roberts C; Metzner M; Garcia-Martin N; Kennedy A; Hamblin A; Raghavan M; Nagra S; Dudley L; Wheatley K; McMullin MF; Pillai SP; Kelly RJ; Siddique S; Dennis M; Cavenagh JD; Vyas P
    Clin Cancer Res; 2017 Nov; 23(21):6430-6440. PubMed ID: 28765326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.